Company intelligence / Profile preview
Tactical Therapeutics
New York, NY, United Statestacticaltherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed three Phase I trials of Carboxyamidotriazole Orotate (CTO) in 44 advanced cancer patients and 42 GBM patients. CTO has shown safety and efficacy in Phase IB. End-of-Phase 1 meeting has been held with FDA. Registration randomized Phase 2 trial is planned in recurrent GBM patients on the Orphan Designation Fast track.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Duke UniversityMemorial Sloan Kettering Cancer Center
Beyond the preview
Go deeper on Tactical Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tactical Therapeutics.